Subscriptions, reports, and dashboards
Avalere Health Advisory's off-the-shelf products give life sciences firms, health plans, and providers ready access to the policy intelligence and market data they need to navigate a shifting healthcare landscape.
Our subscription products
The Policy 360 suite
Federal Policy 360
Anticipate the impact of federal policy
Federal Policy 360 is a subscription service built to help you anticipate how federal health policies impact your business. Drawing on analysis from more than 150 policy experts, it tracks legislative, regulatory, and market-based developments across product reimbursement, payment and delivery reform in the Medicare, Medicaid, and Commercial markets.
Subscribers get comprehensive reports and summaries that translate fast-moving federal actions into clear takeaways for subscribers to adapt their commercial strategies, so they can pivot quickly and stay ahead of the competition.
State Policy 360
Monitor the state policy landscape
State Policy 360 is a subscription service that keeps you current on health policy activity across all 50 states and DC in the following issue areas:
Prescription drug policy
- PDABs and other price control methods
- Copay adjustment programs
- Pharmacy benefit manager reforms
- The 340B Drug Pricing Program
Medicaid
- Expansion, eligibility, and benefits
- Drug benefit management
Coverage and access
- ACA exchanges and the individual market
- AI in healthcare
Our report and dashboard products
Biosimilar and oncology intelligence
Biosimilar Substitution State Statute Report
This is a comprehensive guide to how all 50 states, DC, and Puerto Rico regulate the pharmacy-level substitution of interchangeable biosimilars for their reference biologic products. It provides state-specific answers to questions such as:
- Who’s authorized to make a substitution?
- What circumstances would allow a substitution?
- What are the applicable notification and permission requirements?
Built for manufacturers, providers, health plans, and patient advocates, the report offers a practical starting point for navigating legal requirements that directly affects prescribing, dispensing, and patient access.
Commercial Payers’ use of Oncology Compendia
This dashboard tracks how commercial payers rely on clinical drug compendia such as the NCCN Drugs & Biologics Compendium and Elsevier's Clinical Pharmacology to make off-label oncology coverage decisions. It includes 32 policies available from the top 50 payers (by covered lives) and roughly 209 million covered lives, reflecting the ongoing consolidation reshaping the payer market. Users can search by compendium rating or payer-specific evidence standards, making it a hands-on resource for market access teams, reimbursement hotlines, and account managers working to resolve coverage denials or fill gaps in unclear payer criteria
State Statute Oncology Drug Coverage Report
This report catalogs the state statutes that govern commercial payer coverage of FDA-approved drugs and biologics used off-label for cancer treatment. As of late 2025, 41 states have such statutes on the books, and the report details which compendia each one recognizes, how they're applied, and whether cancer-specific language is included. Because these statutes can override individual payer coverage policies, the report is a valuable supplement for teams supporting coverage and reimbursement strategy or assisting providers with appeals of declined claims.
Our people
